2021 MIPS Measure #450: Trastuzumab Received By Patients With AJCC Stage I (T1c) – III And HER2 Positive Breast Cancer Receiving Adjuvant Chemotherapy 

Measure Type High Priority Measure? Collection Type(s)
Process yes MIPS CQM


Measure Description

Percentage of female patients aged 18 to 70 with stage I (T1c) – III HER2 positive breast cancer for whom appropriate treatment is initiated